Search API
Bavarian Nordic A/S announced today its interim financial results for the first nine months of 2025 and business progress for the third quarter of 2025.
On November 14, 2025, the Company stated that its revenue for the first nine months increased by 32% to DKK 4,793 million, reflecting a strong performance in both Travel Health and Public Preparedness.
Specifically, travel Health revenue increased by 23% to DKK 2,327 million compared to the first nine months of 2024, primarily driven by increased demand for rabies and Tickborne encephalitis vaccines, and supported by the gradual launch of the chikungunya vaccine, Vimkunya®.
Vimkunya is available in the USA, Germany, and France . The global launch has continued throughout the third quarter of 2025, where the vaccine also became available in the United Kingdom and Denmark in September. Vimkunya was also launched in Sweden, Norway, Finland, Italy, and Spain in October.
On February 14, 2025, the U.S. Food and Drug Administration approved Vimkunya for injection for individuals 12 years of age and older who are visiting chikungunya endemic areas such as Cuba.
This travel vaccine is commercailly offered at clinics and travel pharmacies in the USA.
The Lancet Infectious Diseases recently published results from a phase 2 clinical trial of the Lyme disease vaccine candidate, VLA15.
The Valneva SE and Pfizer Inc.-funded study showed a strong immune response following a third booster dose, with a favorable safety profile.
These researchers wrote on November 7, 2025, that the results are consistent with those observed following previous annual booster doses, further supporting the expected benefits of a yearly vaccination before each Lyme season.
They concluded, 'The safety and robust anamnestic immune responses associated with VLA15 boosting support its use as a strategy to increase anti-OspA antibody levels before tick season among children, adolescents, and adults.'
This study's findings are essential to public health as the the Centers for Disease Control and Prevention estimates that approximately 476,000 people in the U.S. are diagnosed and treated for Lyme disease each year, and 132,000 cases are reported annually in Europe.
As of November 14, 2025, VLA15 is the most advanced Lyme disease vaccine candidate.
Taiwan's Centers for Disease Control (TCDC) recently announced four new locally transmitted cases of dengue fever, one each in Xizhi District of New Taipei City, Fengshan District of Kaohsiung City, and Wandan Township of Pingtung County.
The TCDC estimates that there may be a hidden source of this mosquito-transmitted virus in these communities.
Taiwan's public is urged to cooperate with health authorities' prevention and control measures, implement mosquito-breeding site elimination and control measures, and seek medical attention immediately if they develop suspected symptoms.
According to statistics from the TCDC, as of November 10, 2025, there have been a total of 29 confirmed local dengue fever cases this year, residing in Kaohsiung City (14 cases), Taoyuan City (7 cases), Tainan City (3 cases), Pingtung County (2 cases), Yilan County, Taipei City, and New Taipei City (1 case each).
In addition, there have been a total of 223 imported cases, the third-highest number for the same period over the past six years. Most of these cases originated from Southeast Asian countries, with Indonesia (61 cases) being the most common, followed by Vietnam (56 cases), the Philippines (29 cases), and Thailand (23 cases).
The global dengue fever epidemic continues in 2025, with over 4.43 million cases already reported.
To alert international travelers to their health risk, the U.S. CDC has issued a Travel Health Notice regarding dengue outbreaks. As of November 13, 2025, the CDC has not included Taiwan.
From a disease prevention option, the second-generation QDENGA vaccine is authorized in a total of 41 countries.
Since the Zika virus disease was first detected in the Americas in May 2015, over 50 countries and territories in the region have reported cases transmitted by mosquitoes.
Unfortunately, the Federative Republic of Brazil has historically led in the number of cases.
As of November 13, 2025, the Pan American Health Organization (PAHO) reported Brazil has confirmed 22,831 cases of Zika this year alone. Many of these cases are found in the city of Rio de Janeiro, which is home to over 6 million people.
The other countries with the highest case numbers in 2025 include Bolivia, with 1,024 cases, and Argentina, with 892 cases.
Additionally, near the southern border of the United States, Mexico has reported three cases of Zika in 2025, down from 30 cases reported last year.
The PAHO writes, 'While efforts are underway to improve the sensitivity of surveillance systems, a lack of detection is no guarantee that the Zika virus is not circulating or that local transmission has been interrupted.'
Currently, the U.S. CDC reports no geographic areas with an active Zika Travel Health Notice.
The PAHO and the CDC discourage pregnant women from visiting Zika-endemic areas.
From a disease-prevention perspective, one innovative Zika vaccine (VLA1601) is progressing through clinical trials in 2025.
The World Health Organization (WHO) announced today that health authorities in Ethiopia are increasing their response and conducting further investigations following reports of suspected cases of viral hemorrhagic fever in the South Ethiopia Region.
As of November 13, 2025, the WHO has reported eight suspected cases in this region where about 7.5 million people live.
The South Ethiopia Regional State borders Kenya and South Sudan.
Laboratory testing is currently underway to determine the exact cause of these cases. Viral hemorrhagic fever is caused by several distinct families of viruses, including Marburg, Ebola, Crimean-Congo hemorrhagic fever, and Lassa fever.
Currently, only the Zaire Ebola virus has approved vaccines and antibody therapies.
In support of this investigation, the WHO has deployed an initial team of responders and delivered medical supplies to assist in the ongoing efforts to determine the cause of infection and halt further transmission.
Previously, the U.S. CDC included Ethiopia in its Travel Health Notices for malaria, measles, and polio issued in 2025.
Malaria infections in sub-Saharan Africa are increasingly showing resistance to artemisinin-based therapies, posing a significant threat to the effectiveness of antimalarials against the mosquito-transmitted parasite.
However, a novel non-artemisinin antimalarial from Novartis has demonstrated that it is as effective as standard treatment.
On November 12, 2025, Novartis announced positive results from KALUMA, a Phase III study for the new malaria treatment KLU156 (ganaplacide/lumefantrine, or GanLum).
This drug was developed with Medicines for Malaria Venture and met the study's primary non-inferiority endpoint relative to the current standard of care. The treatment achieved a 97.4% PCR-corrected cure rate using an estimand framework, compared to 94% with standard of care.
This data equates to cure rates of 99.2% and 96.7% respectively, based on conventional per-protocol analysis.
"GanLum could represent the biggest advance in malaria treatment for decades, with high efficacy against multiple forms of the parasite as well as the ability to kill mutant strains that are showing signs of resistance to current medicines," said Dr Abdoulaye Djimdé, Professor of Parasitology and Mycology at the University of Science, Techniques and Technologies of Bamako, Mali, in a press release.
"Drug resistance is a growing threat to Africa, so new treatment options can't come a moment too soon."
GanLum is a combination of two compounds that attack the malaria parasite on multiple fronts: ganaplacide, a novel compound with an entirely new mechanism of action, and a new once-daily formulation of the existing antimalarial lumefantrine, a longer-acting treatment.
Ganaplacide is believed to work by disrupting the parasite's internal protein transport systems, which are essential to its survival within red blood cells.3 It belongs to a class of compounds called imidazolopiperazines, first identified as potential antimalarials after a groundbreaking screen of 2.3 million molecules to find drug candidates at Novartis labs in San Diego, California.
Novartis plans to seek regulatory approvals from health authorities for GanLum as soon as possible.
If approved, the drug could be used to treat international travelers returning to the United States after being infected.
For example, in Florida, 43 travel-related malaria cases have been confirmed in 2025, 15 related to travel to Nigeria.
From a malaria prevention option, about 24 countries are now offering malaria vaccinations, but not the USA.
Germany's public health agency announced yesterday that Wild poliovirus type 1 (WPV1) had been recently detected in a sewage sample within this European country.
According to the Federal Ministry, the WPV1 virus likely entered Germany through an individual infected in either Pakistan or Afghanistan, the only two countries where wild polioviruses continue to spread. This type of poliovirus can cause poliomyelitis in people who are not vaccinated or are only partially vaccinated.
The Robert Koch Institute (RKI) wrote on November 12, 2025, that the risk to the general population from polioviruses is considered very low due to high vaccination rates and isolated detection in wastewater. No clinical cases of poliomyelitis have been reported to the RKI to date.
However, the occurrence of a clinical case in unvaccinated individuals cannot be ruled out.
Complete polio vaccination with the inactivated polio vaccine (IPV) used in Germany provides reliable protection against the disease, but only limited protection against infection and transmission.
In September 2025, Germany previously published answers to frequently asked questions about poliomyelitis with a focus on wastewater analysis.
A detailed article on this topic will be published in Epidemiological Bulletin 46/2025 on November 13, 2025.
Currently, Germany is mentioned in the U.S. CDC's Global Polio Travel Health Notice. The CDC also recommends that international travelers be vaccinated with the IPV before traveling abroad in 2025.
Infection with the mpox virus (MPXV) confers stronger immunity against future infection than vaccine-conferred protection, which wanes over time and requires boosting, researchers wrote in The Lancet Infectious Diseases on November 7, 2025.
These findings suggest that MPXV infection confers long-term protection against reinfection, whereas vaccine-induced immunity can wane over time and requires boosting.
These researchers wrote that further studies are needed to determine whether booster doses can enhance the durability of immunological memory in previously vaccinated individuals.
Should booster vaccination prove beneficial, targeted revaccination campaigns will be necessary to maintain population-level protection.
In a related commentary, researchers from the Icahn School of Medicine at Mount Sinai said that the study's findings indicate that the success of next-generation vaccines against orthopoxviruses, such as mpox, will depend on antigen selection that focuses immune responses on proteins associated with long-lasting protection and cross-reactivity against multiple orthopoxviruses.
Currently, the U.S. FDA-approved JYNNEOS (MVA-BN) mpox/smallpox vaccine is offered at clinics and pharmacies in the United States.
Funding for this study was from the Research Foundation–Flanders, Department of Economy, Science and Innovation Flanders, and the Netherlands Organization for Health Research and Development.
